Rituximab-supplemented high-dose sequential chemotherapy (R-HDS) has better EFS and PFS than R-CHOP in poor risk follicular lymphoma (FL) at diagnosis: A multicenter randomized GITMO/IIL trial

M. Ladetto,F. Benedetti,Umberto Vitolo,Caterina Patti,Alessandro Rambaldi,Anna Marina Liberati,Maurizio Musso,Alessandro Pulsoni,A. M. Gianni,Corrado Tarella

Rituximab-supplemented high-dose sequential chemotherapy (R-HDS) has better EFS and PFS than R-CHOP in poor risk follicular lymphoma (FL) at diagnosis: A multicenter randomized GITMO/IIL trial

2006

M. Ladetto
F. Benedetti
Umberto Vitolo
Caterina Patti
Alessandro Rambaldi
Anna Marina Liberati
Maurizio Musso
Alessandro Pulsoni
A. M. Gianni
Corrado Tarella

7525 Background: HDS with ASCT is effective and feasible in FL at the multicenter level and suitable for Rituximab supplementation (R-HDS). This randomized trial compared R-HDS with Rituximab-suppl...

Keywords:

Follicular lymphoma
Rituximab
Cancer research
Immunology
CHOP
Chemotherapy
Medicine
poor risk
Pathology
sequential chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations